Correlation Between Candel Therapeutics and Centessa Pharmaceuticals

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Candel Therapeutics and Centessa Pharmaceuticals at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Candel Therapeutics and Centessa Pharmaceuticals into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Candel Therapeutics and Centessa Pharmaceuticals PLC, you can compare the effects of market volatilities on Candel Therapeutics and Centessa Pharmaceuticals and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Candel Therapeutics with a short position of Centessa Pharmaceuticals. Check out your portfolio center. Please also check ongoing floating volatility patterns of Candel Therapeutics and Centessa Pharmaceuticals.

Diversification Opportunities for Candel Therapeutics and Centessa Pharmaceuticals

-0.44
  Correlation Coefficient

Very good diversification

The 3 months correlation between Candel and Centessa is -0.44. Overlapping area represents the amount of risk that can be diversified away by holding Candel Therapeutics and Centessa Pharmaceuticals PLC in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Centessa Pharmaceuticals and Candel Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Candel Therapeutics are associated (or correlated) with Centessa Pharmaceuticals. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Centessa Pharmaceuticals has no effect on the direction of Candel Therapeutics i.e., Candel Therapeutics and Centessa Pharmaceuticals go up and down completely randomly.

Pair Corralation between Candel Therapeutics and Centessa Pharmaceuticals

Given the investment horizon of 90 days Candel Therapeutics is expected to generate 2.94 times more return on investment than Centessa Pharmaceuticals. However, Candel Therapeutics is 2.94 times more volatile than Centessa Pharmaceuticals PLC. It trades about 0.05 of its potential returns per unit of risk. Centessa Pharmaceuticals PLC is currently generating about 0.02 per unit of risk. If you would invest  701.00  in Candel Therapeutics on September 13, 2024 and sell it today you would earn a total of  74.00  from holding Candel Therapeutics or generate 10.56% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthVery Weak
Accuracy100.0%
ValuesDaily Returns

Candel Therapeutics  vs.  Centessa Pharmaceuticals PLC

 Performance 
       Timeline  
Candel Therapeutics 

Risk-Adjusted Performance

4 of 100

 
Weak
 
Strong
Insignificant
Compared to the overall equity markets, risk-adjusted returns on investments in Candel Therapeutics are ranked lower than 4 (%) of all global equities and portfolios over the last 90 days. Despite quite unsteady fundamental indicators, Candel Therapeutics disclosed solid returns over the last few months and may actually be approaching a breakup point.
Centessa Pharmaceuticals 

Risk-Adjusted Performance

1 of 100

 
Weak
 
Strong
Weak
Compared to the overall equity markets, risk-adjusted returns on investments in Centessa Pharmaceuticals PLC are ranked lower than 1 (%) of all global equities and portfolios over the last 90 days. Despite somewhat strong basic indicators, Centessa Pharmaceuticals is not utilizing all of its potentials. The latest stock price disturbance, may contribute to short-term losses for the investors.

Candel Therapeutics and Centessa Pharmaceuticals Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Candel Therapeutics and Centessa Pharmaceuticals

The main advantage of trading using opposite Candel Therapeutics and Centessa Pharmaceuticals positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Candel Therapeutics position performs unexpectedly, Centessa Pharmaceuticals can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Centessa Pharmaceuticals will offset losses from the drop in Centessa Pharmaceuticals' long position.
The idea behind Candel Therapeutics and Centessa Pharmaceuticals PLC pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Share Portfolio module to track or share privately all of your investments from the convenience of any device.

Other Complementary Tools

Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Latest Portfolios
Quick portfolio dashboard that showcases your latest portfolios
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance